

29 October 2026

QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

QUARTER ENDED 30 SEPTEMBER 2026

Highlights

- **Revenue growth and cash position:** Unaudited revenue grew in each month of the quarter and was ahead of the June quarter. Cash receipts were \$1.0 million and net operating cash outflows were \$2.8 million, including the payment of FY26 short-term incentives and other one-off items. Net operating cash outflows are forecast to drop materially in Q2FY27. The Company repaid the \$400,000 R&D loan facility in full from capital raising proceeds, had \$5.8 million cash at bank at 30 September 2026, and received the FY26 R&D tax incentive refund of \$440,531 from the ATO in early October.
- **Capital raising completed:** Tranche 2 settlement on 11 August 2026 completed the \$9.75 million raising at 7.5 cents per share. On its current plan, the Company is funded through FY27 without a further capital raising.
- **NextLevel OMNI launched:** The NextLevel OMNI iOS speech-generating device secured its Medicare PDAC code on 27 August 2026, with first shipments and revenue in September, with volumes increasing from October through funded partners.
- **US partner channel scaling:** PRC-Salttillo trained a further nine consultants in August and Tobii Dynavox extended its NeuroNode rollout to additional US states.
- **Germany distribution agreement and launch:** NeuroNode distribution agreement with Tobii Dynavox GmbH, launched at RehaCare in Düsseldorf on 23 September 2026. All German sales representatives trained by mid-October
- **NeuroStrip regulatory foundation in place:** NeuroStrip was registered with the US FDA and the UK MHRA (Great Britain) in August 2026 and, after quarter end, CE marked for the European Union. An application to the TGA is pending.
- **NeuroStrip commercial traction:** Approximately 80 organisations are now engaged with NeuroStrip, up from approximately 20 in July, with approximately 30 in live trials and four paying customers. Customer sessions more than doubled on the June quarter.

Control Bionics Limited (ASX: CBL) today released its Quarterly Activities Report and Appendix 4C for the quarter ended 30 September 2026.

Commenting on the quarter, Control Bionics CEO Jeremy Steele said:

The September quarter was about execution. The commercial and regulatory foundations we have built over the past year are now in place, and our focus has shifted to converting them into revenue.

Completing Tranche 2 of our placement in August brought total funds raised to \$9.75 million. We used part of the proceeds to repay our R&D loan facility ahead of receiving our FY26 R&D tax incentive refund, which arrived in early October. On our current plan, the business is funded through FY27, and we do not forecast a further capital raising before reaching cash flow breakeven.

In Assistive Communication, the NextLevel OMNI secured its Medicare PDAC code in late August and delivered first revenue in September. Our US partners continue to train their consultants, with PRC-Salttillo training a further nine in August and Tobii Dynavox extending its rollout to additional states, and in Germany we signed with Tobii Dynavox GmbH. Our experience is that it takes around a quarter for a newly trained partner consultant to deliver a first funded sale, so revenue growth follows consultant training rather than the signing of agreements. Unaudited revenue grew in each month of the quarter and was ahead of the June quarter, and August was our strongest month for NDIS approvals in 12 months.

NeuroStrip is now registered in the US and Great Britain and, since quarter end, CE marked in Europe. The number of organisations engaged has risen to around 80, from around 20 in July, with around 30 in live trials and four paying customers. Converting those trials into paying customers is our priority, and we expect to report the first cohort conversion outcomes in the December quarter.

Operating cash outflows were higher this quarter, which included the payment of FY26 short term incentives and other one-off items. We expect net outflows to moderate materially as partner volumes build, and we reaffirm our expectation of 50% revenue growth in FY27, weighted to the second half.

Operational Performance

(a) North America

North America continued its transition to a partner-led wholesale model during the quarter. PRC-Salttillo trained a further nine consultants in August, with a further 8 to 12 targeted, and Tobii Dynavox extended its NeuroNode rollout to additional US states, with its next consultant group onboarding in the coming weeks. The Company's experience is that a newly trained partner consultant takes approximately one quarter to deliver a first funded sale.

The NextLevel OMNI iOS speech-generating device secured its Medicare PDAC code on 27 August 2026, establishing a Medicare and insurance funding pathway for the device. Shipping commenced and first revenue was recognised in September, with volumes expected to increase from October through funded partners. The Company expects wholesale revenue to become the dominant share of total revenue during the December quarter.

(b) Australia

NDIS approval timeframes remained extended during the quarter, although August was the strongest month for NDIS approvals in 12 months. The Company continues to work directly with customers, the NDIS, industry bodies and stakeholders to shorten approval timeframes.

NeuroStrip engagement in Australia and New Zealand grew strongly, with 37 organisations engaged across elite sport, rehabilitation and research, including Hawthorn, the Brisbane Broncos, Royal Rehab, Rugby Australia, Victoria University and the University of Melbourne.

(c) Japan

The Japan business continued to focus on market development. Existing rehabilitation collaborators continued using NeuroStrip, and discussions with a local health and sports network regarding a potential sales and promotion partnership continued during the quarter.

(d) Other markets

The Company signed a distribution agreement with Tobii Dynavox GmbH for the NeuroNode in Germany, Europe's largest Assistive Communication market, where NeuroNode is reimbursable under statutory health insurance following its inclusion in the German Medical Aids Directory in March 2026. The partnership launched at RehaCare in Düsseldorf on 23 September 2026. The first Tobii Dynavox regional team was trained in August, with the remaining German consultants trained in mid-October. The agreement is non-exclusive, has an initial term of 12 months and contains no minimum purchase commitment.

In the United Kingdom, NeuroStrip was registered with the MHRA, enabling commercial supply across Great Britain. Three pilot programs are underway, including with the University

of Nottingham and British Olympic programs. After quarter end, NeuroStrip was CE marked as a Class I medical device under the EU Medical Device Regulation, enabling supply across the European Union, the European Economic Area and Northern Ireland.

(e) Product development

NeuroStrip was registered and listed with the US FDA as a medical device in August 2026, strengthening its positioning with clinical rehabilitation providers and research institutions. NeuroStrip now holds registrations in the US, Great Britain and the European Union, and a TGA application is pending.

Customer use of NeuroStrip continued to grow, with 282 customer sessions recorded in the quarter, up 103% on the June quarter, across 28 customer organisations. re/Compete, the Company's first repeatable NeuroStrip prehabilitation program for physiotherapists, launches in the US in November.

Apple BCI integration has been operating in beta with customers since November 2025. General release is now expected in Q2 FY27, delivered through the upgraded NeuroNode Controller App.

Quarterly cash flows and cash at bank

The Group's results reflect the following:

- Customer receipts of approximately \$1.0 million, in line with the June quarter. Revenue growth during the quarter was weighted to September and is expected to be reflected in receipts in the December quarter.
- Net operating cash outflows of approximately \$2.8 million which included approximately \$800,000 of payments not expected to recur in FY27, including FY26 short-term incentives accrued at 30 June 2026 and other one-off items.
- Net investing cash outflows of approximately \$0.2 million, comprising expenditure on intellectual property (\$0.10m) and property, plant and equipment (\$0.06m).
- Net cash inflow from financing activities of approximately \$6.6 million, reflecting proceeds from Tranche 2 of the placement and the Share Purchase Plan net of transaction costs of \$0.04m, partly offset by repayment of the \$0.04m R&D loan facility ahead of receipt of the R&D tax incentive refund, and scheduled repayments under the Attvest insurance funding arrangement.
- A closing cash balance of approximately \$5.8 million at 30 September 2026 (30 June \$2.1m). The FY26 R&D tax incentive refund of \$440,531 was received in early October 2026 and is not included in the quarter-end cash balance.

ASX Additional information**Expenditure on business activities**

Pursuant to Listing Rule 4.7C.1, a summary of the expenditure incurred on the above business activities for the quarter:

Expenditure Category	Amount \$'000
Staff costs	1,832
Product manufacturing	1,092
Administration and corporate	587
Research and development	85
Advertising and marketing	146

Related Party Payments

Related party payments as noted in Item 6.1 of the Appendix 4C comprise a total amount of \$242,199, being salary paid to Executive Directors and their related parties, Board fees paid to Non-Executive Directors, the CEO's FY26 short-term incentive of \$97,500 accrued at 30 June 2026 and paid during the quarter, and consulting fees of \$12,833 paid to Professor Nicholas Opie for strategic advisory services provided during FY26.

This ASX announcement has been approved for release by the Board of Directors of Control Bionics Limited.

For further information, please contact:

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.

Forward-looking statements

This announcement contains forward-looking statements, including statements regarding expected revenue and operating cash flows, FY27 revenue growth, NextLevel OMNI volumes, the rollout of the German distribution agreement, the conversion of NeuroStrip trials, the timing of the Apple BCI general release and the Company's expected path to cash flow breakeven. Forward-looking statements are based on current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control, and actual results may differ materially from those expressed or implied. The Company does not undertake to update or revise any forward-looking statements except as required by law, and no representation or warranty is given as to the accuracy, likelihood of achievement or reasonableness of any forward-looking statement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Control Bionics Limited

ABN

45 115 465 462

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter (\$A'000)	Year to date (3 months) (\$A'000)
1. Cash flows from operating activities		
1.1 Receipts from customers	999	999
1.2 Payments for		
research and development	(85)	(85)
product manufacturing and operating costs	(1,092)	(1,092)
advertising and marketing	(146)	(146)
leased assets	(13)	(13)
staff costs	(1,832)	(1,832)
administration and corporate costs	(587)	(587)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	24	24
1.5 Interest and other costs of finance paid	(20)	(20)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material) ¹	-	-
1.9 Net cash from / (used in) operating activities	(2,752)	(2,752)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	businesses	-	-
	property, plant and equipment	(56)	(56)
	investments	-	-
	intellectual property	(100)	(100)
	other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	businesses	-	-
	property, plant and equipment	-	-
	investments	-	-
	intellectual property	-	-
	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (cash acquired on business acquisition)	-	-
2.6	Net cash from / (used in) investing activities	(156)	(156)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	7,499	7,499
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(397)	(397)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(467)	(467)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	6,635	6,635

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,077	2,077
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,752)	(2,752)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(156)	(156)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,635	6,635
4.5	Effect of movement in exchange rates on cash held	(12)	(12)
4.6	Cash and cash equivalents at end of period	5,792	5,792

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,792	2,077
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,792	2,077

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	242
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end \$A’000	Amount drawn at quarter end \$A’000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Insurance Funding Arrangement) – see below	(21)	(21)
7.4	Total financing facilities	(21)	(21)
7.5	Unused financing facilities available at quarter end		-
7.6	<p>Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p> <p>On 28 April 2026, the Company entered into a \$400,000 loan facility with Phoenix Development Fund Limited as an advance against the Company’s anticipated FY26 R&D tax incentive refund. The loan was unsecured, bore interest at 12% per annum and was repayable on the earlier of 30 September 2026 and receipt of the refund. Following completion of the capital raising, the Company elected to repay the loan in full on 11 August 2026, together with interest of \$14,120, ahead of receiving the refund. The FY26 R&D tax incentive refund of \$440,531 was received in early October 2026. No amount remains available under the facility.</p> <p>On 28 January 2026, the Company entered into an insurance premium funding arrangement with Attvest Finance (“Attvest”) to fund the renewal of its insurance policies. The facility is unsecured, repayable in 10 monthly instalments to 30 October 2026 and incorporates a flat interest rate of 4.67% over the term. The outstanding balance of the facility is \$21,334 as at 30 September 2026. No additional financing facilities have been entered into since quarter end. Consistent with prior years, the Company expects to enter into a new insurance premium funding arrangement on renewal of its insurance policies in January 2027, to spread the cost of annual premiums over the policy term.</p>		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,752)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,792
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,792
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	<p>Answer: Item 8.5 exceeds two quarters and answers to item 8.6 are not required. The Company provides the following information to assist the market. The Company does not expect net operating cash outflows to continue at the level reported for the quarter. Outflows of \$2.8 million included approximately \$0.8 million of payments not expected to recur in FY27, including FY26 short-term incentives accrued at 30 June 2026 and other one-off items. Customer receipts did not yet reflect revenue growth during the quarter, with unaudited revenue increasing in each month and ahead of the June quarter. The Company expects net operating cash outflows to materially reduce over coming quarters as NextLevel OMNI volumes ramp from October following the Medicare PDAC code secured in August, NeuroNode wholesale volumes grow as Tobii Dynavox and PRC-Salttillo onboard further consultants in the US and Tobii Dynavox GmbH rolls out in Germany, and NeuroStrip trials convert to paying customers. The Company expects the Assistive Communication business to be profitable on a monthly basis during H1 FY27, and expects FY27 revenue growth of 50% on FY26, weighted to the second half.</p>	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	<p>Answer: The Company completed a \$9.75 million capital raising at 7.5 cents per share, comprising a two-tranche placement and a Share Purchase Plan. Tranche 1 (29,935,788 shares) settled on 30 June 2026 and 3,419,993 shares were issued under the Share Purchase Plan on 21 July 2026. Tranche 2 (96,700,000 shares, including shares issued to Directors) was approved by shareholders on 6 August 2026 and settled on 11 August 2026. The proceeds received during the quarter are reflected in the cash balance of \$5.8 million at 30 September 2026. The Company used part of the proceeds to repay its \$400,000 R&D loan facility on 11 August 2026, ahead of receiving its FY26 R&D tax incentive refund of \$440,531 in early October 2026. Based on its current operating plan, the Company does not forecast a further capital raising before reaching cash flow breakeven, and no further steps to raise cash are currently proposed. The Company continues to maintain regular engagement with investors and funding counterparties.</p>	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The Company expects to be able to continue its operations and meet its business objectives on the basis of its cash balance of \$5.8 million at 30 September 2026, following completion of the capital raising and repayment of the R&D loan facility, together with the FY26 R&D tax incentive refund of \$440,531 received in early October 2026. The Board monitors performance monthly against the Company's FY27 operating plan, under which the business is funded through FY27 and reaches cash flow breakeven without further capital raising. This is supported by increasing commercial momentum, including first NextLevel OMNI revenue following the Medicare PDAC code, expanding NeuroNode wholesale distribution through Tobii Dynavox and PRC-Salttillo in the US and Tobii Dynavox GmbH in Germany, and NeuroStrip regulatory registrations in the US, Great Britain and the European Union supporting conversion of its growing trial base.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1. This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2. This statement gives a true and fair view of the matters disclosed.

Date: *29 October 2026*

Authorised by: By the Board